IMVT-1401

Immunovant stock loses half its value after pausing dosing in trial of thyroid eye disease treatment
Marketwatch
Tue, 02/2/21 - 10:42 am
Immunovant
thyroid eye disease
clinical trials
IMVT-1401
Following the pack, Immunovant rushes into pivotal studies
EP Vantage
Wed, 08/26/20 - 11:00 am
Immunovant
clinical trials
myasthenia gravis
IMVT-1401
Important catalysts approach for smaller biotechs
EP Vantage
Wed, 06/24/20 - 10:35 am
BeiGene
Turning Point Therapeutics
Intra-Cellular Therapies
Immunovant
Caplyta
Brukinsa
repotrectinib
IMVT-1401
clinical trials
Newly-public Immunovant announces first proof-of-concept success
Endpoints
Mon, 03/30/20 - 10:38 am
Immunovant
thyroid eye disease
IMVT-1401
clinical trials